Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.
Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for those interested in joining the study, along with a reference to the Contacts and Locations section.SummaryDifference3%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedSeveral key resources and links related to genetics and rare diseases have been removed, including MedlinePlus and NIH links, which may impact access to important health information.SummaryDifference4%
- Check36 days agoChange DetectedNew resources related to genetics, rare diseases, and drug information have been added, including links to MedlinePlus, NIH, and DailyMed, which may be of particular interest for those researching lung cancer and neuroendocrine tumors.SummaryDifference0.5%
- Check43 days agoChange DetectedThe website has been updated to version v2.12.2, adding new features for downloading study data in various formats and displaying detailed participant and study information, while the previous version v2.12.1 has been removed.SummaryDifference4%
- Check50 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.